ReviewReviews on recent clinical trials2015
PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.
Review in Reviews on recent clinical trials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Identification of Factors Affecting Prostate Cancer Using Machine Learning Methods: A Systematic Review.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.Cancer · 2017Trial
- Genome-scale molecular profiling from routine histopathology with a multimodal pathology foundation model.Research square · 2026Article
- Longitudinal characterization of mosaic chromosomal alterations identifies factors influencing clonal dynamics of leukocytes.Nature communications · 2026Article
- Estrogen metabolism-related lifestyle score and risk of postmenopausal breast, endometrial, and ovarian cancers: findings from two large prospective cohort studies.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Article
- Missed colorectal cancer diagnosis by screening colonoscopy based on the PLCO cancer screening trial.International journal of colorectal disease · 2025Article
- Pancancer outcome prediction via a unified weakly supervised deep learning model.Signal transduction and targeted therapy · 2025Article
- Assessing the risk of second primary lung cancer in women after previous breast cancer.BJC reports · 2025Article
- Prediagnostic whole-blood cadmium and molybdenum associated with pancreatic cancer in an American cohort.American journal of epidemiology · 2025Article
- Article
- NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.Biomolecules · 2025Review
- Metabolic Dysregulation and Cancer Risk Program (MeDOC): a transdisciplinary approach to obesity-associated cancers.Journal of the National Cancer Institute · 2024Article
- Article
- Article
- Article
- Article
- Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients.Nature communications · 2023Article
- GWAS Explorer: an open-source tool to explore, visualize, and access GWAS summary statistics in the PLCO Atlas.Scientific data · 2023Article
- PLCOjs, a FAIR GWAS web SDK for the NCI Prostate, Lung, Colorectal and Ovarian Cancer Genetic Atlas project.Bioinformatics (Oxford, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), a large-scale, multi-institutional, randomized controlled trial, was launched in 1992 to evaluate the effectiveness of screening modalities for prostate, lung, colorectal, and ovarian cancer. However, PLCO was additionally designed to serve as an epidemiologic resource and the National Cancer Institute has invested substantial resources over the years to accomplish this goal. In this report, we provide a summary of changes to PLCO's follow-up after conclusion of the screening phase of the trial and highlight recent data and biospecimen collections, including ancillary studies, geocoding, administration of a new medication use questionnaire, consent for linkage to Medicare, and additional tissue collection that enhance the richness of the PLCO resource and provide further opportunities for scientific investigation into the prevention, early detection, etiology and treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.